Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Janux Therapeutics, Inc. (JANX) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Janux Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1817713.
Total stock buying since 2021: $195,374,862.
Total stock sales since 2021: $366,447,916.
Total stock option exercises since 2021: $857,200.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 824,041 | $25,441,692 | 18,335 | $758,259 | 13,335 | $56,139 |
| 2024 | 1,200,000 | $53,700,000 | 6,645,716 | $344,511,755 | 80,750 | $801,061 |
| 2023 | 3,044,570 | $21,133,725 | 0 | $0 | 0 | $0 |
| 2021 | 5,594,085 | $95,099,445 | 1,106,200 | $21,177,902 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-05 | 0 | $0 | 3,333 | $107,575 | 3,333 | $14,031 |
| 2025-04 | 0 | $0 | 3,334 | $100,020 | 3,334 | $14,036 |
| 2025-03 | 824,041 | $25,441,692 | 3,334 | $107,914 | 3,334 | $14,036 |
| 2025-02 | 0 | $0 | 3,334 | $142,745 | 3,334 | $14,036 |
| 2025-01 | 0 | $0 | 5,000 | $300,005 | 0 | $0 |
| 2024-12 | 0 | $0 | 15,000 | $1,005,000 | 9,881 | $169,261 |
| 2024-11 | 0 | $0 | 25,000 | $1,293,375 | 0 | $0 |
| 2024-10 | 1,200,000 | $53,700,000 | 1,698,128 | $83,209,454 | 12,284 | $247,988 |
| 2024-09 | 0 | $0 | 1,084,867 | $49,709,952 | 58,585 | $383,812 |
| 2024-06 | 0 | $0 | 3,822,721 | $209,293,974 | 0 | $0 |
| 2023-11 | 2,549,562 | $14,965,926 | 0 | $0 | 0 | $0 |
| 2023-07 | 495,008 | $6,167,799 | 0 | $0 | 0 | $0 |
| 2021-12 | 0 | $0 | 1,106,200 | $21,177,902 | 0 | $0 |
| 2021-06 | 5,594,085 | $95,099,445 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-01 | Meyer Andrew Hollman (Chief Business Officer) | Sale | 3,333 | 32.28 | 107,575 |
| 2025-05-01 | Meyer Andrew Hollman (Chief Business Officer) | Option Ex | 3,333 | 4.21 | 14,031 |
| 2025-04-21 | Meyer Andrew Hollman (Chief Business Officer) | Sale | 3,334 | 30.00 | 100,020 |
| 2025-04-21 | Meyer Andrew Hollman (Chief Business Officer) | Option Ex | 3,334 | 4.21 | 14,036 |
| 2025-03-07 | Shah Rajeev M. | Buy | 110,206 | 31.02 | 3,418,590 |
| 2025-03-06 | Shah Rajeev M. | Buy | 372,093 | 30.78 | 11,453,022 |
| 2025-03-05 | Shah Rajeev M. | Buy | 341,742 | 30.93 | 10,570,080 |
| 2025-03-03 | Meyer Andrew Hollman (Chief Business Officer) | Sale | 3,334 | 32.37 | 107,914 |
| 2025-03-03 | Meyer Andrew Hollman (Chief Business Officer) | Option Ex | 3,334 | 4.21 | 14,036 |
| 2025-02-03 | Meyer Andrew Hollman (Chief Business Officer) | Sale | 3,334 | 42.81 | 142,745 |
| 2025-02-03 | Meyer Andrew Hollman (Chief Business Officer) | Option Ex | 3,334 | 4.21 | 14,036 |
| 2025-01-07 | Campbell David Alan (President and CEO) | Sale | 5,000 | 60.00 | 300,005 |
| 2024-12-19 | Meyer Andrew Hollman (Chief Business Officer) | Option Ex | 9,881 | 17.13 | 169,261 |
| 2024-12-03 | Campbell David Alan (President and CEO) | Sale | 15,000 | 67.00 | 1,005,000 |
| 2024-11-25 | Campbell David Alan (President and CEO) | Sale | 25,000 | 51.73 | 1,293,375 |
| 2024-10-28 | Campbell David Alan (President and CEO) | Sale | 25,000 | 53.58 | 1,339,550 |
| 2024-10-18 | Shah Rajeev M. | Buy | 1,200,000 | 44.75 | 53,700,000 |
| 2024-10-18 | Lichter Jay | Sale | 1,461,769 | 48.74 | 71,251,006 |
| 2024-10-17 | Lichter Jay | Sale | 1,843 | 50.02 | 92,186 |
| 2024-10-17 | Lichter Jay | Option Ex | 1,769 | 20.19 | 35,712 |
| 2024-10-16 | Lichter Jay | Sale | 209,516 | 50.24 | 10,526,712 |
| 2024-10-16 | Lichter Jay | Option Ex | 10,515 | 20.19 | 212,276 |
| 2024-09-30 | Lichter Jay | Sale | 958 | 46.24 | 44,297 |
| 2024-09-30 | Lichter Jay | Option Ex | 919 | 20.19 | 18,552 |
| 2024-09-27 | Diraimondo Thomas (Chief Scientific Officer) | Sale | 5,000 | 46.72 | 233,575 |
| 2024-09-27 | Meyer Andrew Hollman (Chief Business Officer) | Sale | 50,000 | 45.95 | 2,297,750 |
| 2024-09-27 | Meyer Andrew Hollman (Chief Business Officer) | Option Ex | 50,000 | 4.21 | 210,500 |
| 2024-09-27 | Campbell David Alan (President and CEO) | Sale | 25,000 | 46.93 | 1,173,200 |
| 2024-09-27 | Lichter Jay | Sale | 106,821 | 46.95 | 5,015,566 |
| 2024-09-27 | Lichter Jay | Option Ex | 1,752 | 20.19 | 35,369 |
| 2024-09-26 | Lichter Jay | Sale | 200,000 | 47.27 | 9,455,000 |
| 2024-09-13 | Lichter Jay | Sale | 3,815 | 46.68 | 178,084 |
| 2024-09-13 | Lichter Jay | Option Ex | 3,815 | 20.19 | 77,017 |
| 2024-09-12 | Lichter Jay | Sale | 350,000 | 47.00 | 16,450,000 |
| 2024-09-10 | Lichter Jay | Sale | 101,091 | 46.40 | 4,690,116 |
| 2024-09-09 | Lichter Jay | Sale | 2,182 | 42.33 | 92,364 |
| 2024-09-09 | Lichter Jay | Option Ex | 2,099 | 20.19 | 42,374 |
| 2024-09-06 | Lichter Jay | Sale | 240,000 | 42.00 | 10,080,000 |
| 2024-06-03 | Avalon Bioventures Spv I, L.p. | Sale | 1,500,000 | 54.75 | 82,125,000 |
| 2024-06-03 | Reardon Tighe (Acting Chief Financial Officer) | Sale | 822,721 | 54.75 | 45,043,974 |
| 2024-06-03 | Lichter Jay | Sale | 1,500,000 | 54.75 | 82,125,000 |
| 2023-11-13 | Avalon Bioventures I, Lp (10% Owner) | Buy | 849,854 | 5.87 | 4,988,642 |
| 2023-11-13 | Reardon Tighe (Acting Chief Financial Officer) | Buy | 849,854 | 5.87 | 4,988,642 |
| 2023-11-13 | Lichter Jay (Director) | Buy | 849,854 | 5.87 | 4,988,642 |
| 2023-07-19 | Shah Rajeev M. | Buy | 495,008 | 12.46 | 6,167,799 |
| 2021-12-29 | Orbimed Genesis Gp Llc | Sale | 40,400 | 20.30 | 820,120 |
| 2021-12-29 | Thompson Peter A. | Sale | 40,400 | 20.30 | 820,120 |
| 2021-12-21 | Orbimed Genesis Gp Llc | Sale | 119,400 | 19.00 | 2,268,600 |
| 2021-12-21 | Thompson Peter A. | Sale | 119,400 | 19.00 | 2,268,600 |
| 2021-12-16 | Orbimed Genesis Gp Llc | Sale | 393,300 | 19.07 | 7,500,231 |
| 2021-12-16 | Thompson Peter A. | Sale | 393,300 | 19.07 | 7,500,231 |
| 2021-06-15 | Bregua Corp (10% Owner) | Buy | 58,823 | 17.00 | 999,991 |
| 2021-06-15 | Avalon Bioventures Spv I, L.p. (10% Owner) | Buy | 629,411 | 17.00 | 10,699,987 |
| 2021-06-15 | Orbimed Genesis Gp Llc (Director) | Buy | 705,853 | 17.00 | 11,999,501 |
| 2021-06-15 | Reardon Tighe (Acting Chief Financial Officer) | Buy | 629,411 | 17.00 | 10,699,987 |
| 2021-06-15 | Shah Rajeev M. | Buy | 2,941,176 | 17.00 | 49,999,992 |
| 2021-06-15 | Lichter Jay (Director) | Buy | 629,411 | 17.00 | 10,699,987 |
Insider trading activities including stock purchases, stock sales, and option exercises of JANX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Janux Therapeutics, Inc. (symbol JANX, CIK number 1817713) see the Securities and Exchange Commission (SEC) website.